solanezumab   Click here for help

GtoPdb Ligand ID: 6932

Synonyms: LY-2062430
Compound class: Antibody
Comment: Solanezumab is an investigational humanized monoclonal antibody targeting amyloid-β (Aβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. The invention of solanezumab is covered by patent US7195761 [2], where it is coded as Hu266.
1. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS et al.. (2014)
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
N Engl J Med, 370 (4): 311-21. [PMID:24450890]
2. Holtzman DM, DeMattos R, Bales KR, Paul SM, Tsurushita N, Vasquez M. (2007)
Humanized antibodies that sequester abeta peptide.
Patent number: US7195761. Assignee: Eli Lilly And Company, Washington University. Priority date: 24/02/2002. Publication date: 27/03/2007.
3. Imbimbo BP, Ottonello S, Frisardi V, Solfrizzi V, Greco A, Seripa D, Pilotto A, Panza F. (2012)
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.
Expert Rev Clin Immunol, 8 (2): 135-49. [PMID:22288451]
4. Tayeb HO, Murray ED, Price BH, Tarazi FI. (2013)
Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?.
Expert Opin Biol Ther, 13 (7): 1075-84. [PMID:23574434]